Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pradigastat in Non-alcoholic Fatty Liver Disease
NCT01811472Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2013
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pradigastat in non-alcoholic fatty liver disease (NAFLD), sponsored by Novartis. Started Jun 2013; status: completed.
02
Drugs
pradigastat
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT01811472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01811472.